Please login to the form below

Not currently logged in
Email:
Password:

sofosbuvir

This page shows the latest sofosbuvir news and features for those working in and with pharma, biotech and healthcare.

Gilead wins European approval for triple hep C combination Vosevi

Gilead wins European approval for triple hep C combination Vosevi

Gilead wins European approval for triple hep C combination Vosevi. The treatment brings together sofosbuvir, velpatasvir and voxilaprevir. ... Gilead Sciences has chalked up a big win with its hepatitis C treatment Vosevi

Latest news

  • Merck & Co pulls out of hepatitis C R&D as market shrinks Merck & Co pulls out of hepatitis C R&D as market shrinks

    In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half

  • Gilead makes $11.9bn play for CAR-T specialist Kite Gilead makes $11.9bn play for CAR-T specialist Kite

    Gilead's deal comes as it faces a sharp slowdown in sales of its HCV therapies - led by Harvoni (sofosbuvir and ledipasvir) and Sovaldi (sofosbuvir) - which has led investors to call

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    first treatment approved for patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or other drugs for HCV that inhibit a protein called NS5A". ... Gilead has also filed for the sofosbuvir, velpatasvir and voxilaprevir

  • Samsung Bioepis wins CHMP nod for second Humira biosimilar Samsung Bioepis wins CHMP nod for second Humira biosimilar

    virus (infection) - AbbVie's Maviret (glecaprevir/pibrentasvir) and Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir). ... Both were reviewed under the accelerated assessment protocol because despite the robust efficacy of current drugs such as Gilead

  • Two new hepatitis C therapies fast-tracked in Europe Two new hepatitis C therapies fast-tracked in Europe

    Gilead's application is for a three drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir – given over 12 weeks – that could achieve a ... Sofosbuvir and velpatasvir are

More from news
Approximately 29 fully matching, plus 96 partially matching documents found.

Latest Intelligence

  • When science is not enough When science is not enough

    Witness Gilead’s hepatitis C drug sovaldi (sofosbuvir) which has glowing efficacy results yet is having a troubled transition into the market place.

  • Taking a strategic approach Taking a strategic approach

    a warning from the WHO on the cost of new treatments for hepatitis C, with the likes of Gilead's Sovaldi (sofosbuvir) in particular having been a lightning rod for the

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    Gilead Sciences has emerged as the leader in this field with Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), both of which have already made billions of dollars.

  • Pharma deals during June 2014 Pharma deals during June 2014

    Idenix' negotiation position will have been helped no end by the price and recent US sales of Gilead's Sovaldi (sofosbuvir); the US price is $84, 000 (for a 12 week

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics